HomeAI · summaries
Storia in 5 fonti
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Pfizer (NYSE:PFE)
FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab (Keytruda, Merck) or pembrolizumab and…
- ·
medpagetoday.com
FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting
Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility
